Evidence map›Paper›PMID 38054579›Full record

ArticleJournal of the International AIDS Society2023

Population-level effectiveness of pre-exposure prophylaxis for HIV prevention among men who have sex with men in Montréal (Canada): a modelling study of surveillance and survey data.

Carla M Doyle, Rachael M Milwid, Joseph Cox, Yiqing Xia, Gilles Lambert, Cécile Tremblay, Joanne Otis, Marie-Claude Boily, Jean-Guy Baril, Réjean Thomas and 6 more

Open access · goldAbstract read
In one paragraph

Article in Journal of the International AIDS Society, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 8 institutions in 2 countries.

Carla M DoyleDepartment of Epidemiology and Biostatistics, School of Population and Global Health, McGill University, Montréal, Québec, Canada.ORCID 0000-0001-5104-3068
Rachael M MilwidDepartment of Epidemiology and Biostatistics, School of Population and Global Health, McGill University, Montréal, Québec, Canada.
Joseph CoxDepartment of Epidemiology and Biostatistics, School of Population and Global Health, McGill University, Montréal, Québec, Canada.
Yiqing XiaDepartment of Epidemiology and Biostatistics, School of Population and Global Health, McGill University, Montréal, Québec, Canada.
Gilles LambertDirection Régionale de Santé Publique de Montréal, Montréal, Québec, Canada.
Cécile TremblayCentre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montréal, Québec, Canada.
Joanne OtisDépartement de Sexologie, Université du Québec à Montréal, Montréal, Québec, Canada.
Marie-Claude BoilyMRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, UK.
Jean-Guy BarilDepartment of Family Medicine, Centre Hospitalier de l'Université de Montréal, Montréal, Québec, Canada.
Réjean ThomasClinique médicale l'Actuel, Montréal, Québec, Canada.
Alexandre Dumont BlaisRÉZO Health and STI prevention for GBQ men, trans people and MSM, Montréal, Québec, Canada.
Benoit TrottierClinique de médecine urbaine du Quartier Latin, Montréal, Québec, Canada.
Daniel GraceDalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
David M MooreBC Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.ORCID 0000-0003-1078-9247
Sharmistha MishraDepartment of Medicine, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.ORCID 0000-0001-8492-5470
Mathieu Maheu-GirouxDepartment of Epidemiology and Biostatistics, School of Population and Global Health, McGill University, Montréal, Québec, Canada.ORCID 0000-0002-8363-4388
McGill University · CACentre Hospitalier de l’Université de Montréal · CAImperial College London · GBMcGill University Health Centre · CASt. Michael's Hospital · CAUniversité du Québec à Montréal · CAUniversity of British Columbia · CAUniversity of Toronto · CA

Funding

Medical Research Council MR/X020258/1
6 · The paper itself

Abstract

introductionHIV pre-exposure prophylaxis (PrEP) has been recommended and partly subsidized in Québec, Canada, since 2013. We evaluated the population-level impact of PrEP on HIV transmission among men who have sex with men (MSM) in Montréal, Québec's largest city, over 2013-2021.

methodsWe used an agent-based mathematical model of sexual HIV transmission to estimate the fraction of HIV acquisitions averted by PrEP compared to a counterfactual scenario without PrEP. The model was calibrated to local MSM survey, surveillance, and cohort data and accounted for COVID-19 pandemic impacts on sexual activity, HIV prevention, and care. PrEP was modelled from 2013 onwards, assuming 86% individual-level effectiveness. The PrEP eligibility criteria were: any anal sex unprotected by condoms (past 6 months) and either multiple partnerships (past 6 months) or multiple uses of post-exposure prophylaxis (lifetime). To assess potential optimization strategies, we modelled hypothetical scenarios prioritizing PrEP to MSM with high sexual activity (≥11 anal sex partners annually) or aged ⩽45 years, increasing coverage to levels achieved in Vancouver, Canada (where PrEP is free-of-charge), and improving retention.

resultsOver 2013-2021, the estimated annual HIV incidence decreased from 0.4 (90% credible interval [CrI]: 0.3-0.6) to 0.2 (90% CrI: 0.1-0.2) per 100 person-years. PrEP coverage among HIV-negative MSM remained low until 2015 (<1%). Afterwards, coverage increased to a maximum of 10% of all HIV-negative MSM, or about 16% of the 62% PrEP-eligible HIV-negative MSM in 2020. Over 2015-2021, PrEP averted an estimated 20% (90% CrI: 11%-30%) of cumulative HIV acquisitions. The hypothetical scenarios modelled showed that, at the same coverage level, prioritizing PrEP to high sexual activity MSM could have averted 30% (90% CrI: 19%-42%) of HIV acquisitions from 2015-2021. Even larger impacts could have resulted from higher coverage. Under the provincial eligibility criteria, reaching 10% coverage among HIV-negative MSM in 2015 and 30% in 2019, like attained in Vancouver, could have averted up to 63% (90% CrI: 54%-70%) of HIV acquisitions from 2015 to 2021.

conclusionsPrEP reduced population-level HIV transmission among Montréal MSM. However, our study suggests missed prevention opportunities and adds support for public policies that reduce PrEP barriers, financial or otherwise, to MSM at risk of HIV acquisition.

Indexed as

Anti-HIV AgentsHIV InfectionsPre-Exposure ProphylaxisSexual and Gender MinoritiesAgedCanadaHomosexuality, MaleHumansMalePandemicsSexual BehaviorAnti-HIV Agentsantiretroviralcombination preventioneliminationepidemiologyimpact evaluationmathematical modellingsexually transmitted and blood-borne infections

Identifiers

PMID38054579
PMCPMC10699110
OpenAlexW4389390464

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.